Regeneron's COVID-19 treatment
GPTKB entity
Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Lonza_Group
|
| gptkbp:appointed_by |
gptkb:hospital
intravenous infusion non-hospitalized patients |
| gptkbp:approves |
gptkb:U._S._Food_and_Drug_Administration
|
| gptkbp:associated_with |
reduced viral load
|
| gptkbp:can_be_used_with |
other COVID-19 therapies
two monoclonal antibodies |
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:developed_by |
gptkb:Regeneron_Pharmaceuticals
gptkb:COVID-19_pandemic humanized mice |
| gptkbp:emergency_services |
gptkb:2020
|
| gptkbp:has |
limited shelf life
been used in clinical studies specific dosing regimen |
| https://www.w3.org/2000/01/rdf-schema#label |
Regeneron's COVID-19 treatment
|
| gptkbp:indication |
mild to moderate COVID-19
|
| gptkbp:involves |
patient monitoring
|
| gptkbp:is |
subject to regulatory review
subject to ongoing research administered as soon as possible after diagnosis a response to global health crisis not recommended for patients requiring hospitalization a combination therapy administered in outpatient settings an example of rapid drug development an important tool in managing COVID-19 outbreaks an investigational product considered for emergency situations not a cure for COVID-19 not a substitute for vaccination not effective for severe COVID-19 cases part of Regeneron's therapeutic portfolio part of a broader treatment strategy for COVID-19 part of post-exposure prophylaxis strategy used to prevent progression of disease |
| gptkbp:is_available_in |
multiple countries
|
| gptkbp:is_effective_against |
variants of SARS-Co V-2
|
| gptkbp:is_studied_in |
high-risk patients
|
| gptkbp:marketed_as |
gptkb:REGEN-COV
|
| gptkbp:part_of |
Regeneron's COVID-19 response strategy
clinical guidelines for COVID-19 treatment |
| gptkbp:reduces |
hospitalization rates
death rates |
| gptkbp:requires |
prescription
cold chain storage |
| gptkbp:targets |
SARS-Co V-2 virus
|
| gptkbp:uses |
monoclonal antibodies
|